Company Product Description Indication Status
Neon Therapeutics Inc., of Cambridge, Mass. NEO-PTC-01 Autologous T-cell therapy Stage IV melanoma Filed a CTA with the Dutch Health Authority for evaluation in patients with metastatic melanoma who are refractory to checkpoint inhibitors
Seattle Genetics Inc., of Bothell, Wash. Tucatinib Erbb2 tyrosine kinase receptor inhibitor Metastatic breast cancer FDA granted breakthrough therapy status to tucatinib, in combination with trastuzumab and capecitabine, for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who have been treated with trastuzumab, pertuzumab and T-DM1

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments